No benefit in antidepressant drug for COVID-19 treatment: Study
- Fluvoxamine lacks effect in treating COVID-19
- 2021 reports suggested it reduced hospitalization
- It costs $4 compared to $2000 for antibody treatments
FILE – This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases – Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
ovp test
Male shot by female at Shreveport apartment
Class to create biodiverse backyard
Rules for outbursts at Caddo School Board Meeting
(NewsNation) — An antidepressant drug that was touted as a cheap treatment now shows no effects for patients with COVID-19, according to a new study.
In 2021, multiple reports came out suggesting that the pill, called fluvoxamine, reduced the need for hospitalization among high-risk adults with COVID-19.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies. Now, a JAMA Network study reports it does not shorten the duration of symptoms in adults with mild to moderate COVID-19.
The clinical trial sought to determine whether a 100 mg dosage of fluvoxamine, taken twice daily for 13 days, could reduce the duration of symptoms in outpatient adults (aged 30 or over) with mild to moderate COVID-19 when compared to a placebo.
Best Prime Day Deals for 2024:
— Products still on sale after Prime Big Deal Days
— Beats headphones and tablets remain marked down
— Make sure you’re stocked with Apple products
BestReviews is reader-supported and may earn an affiliate commission.
The trial, which included 1,175 participants enrolled when omicron COVID-19 subvariants were prevalent, found no significant difference in the time to sustained recovery between the fluvoxamine group and the placebo group.
Fluvoxamine as a treatment was a positive development during the pandemic due to its low cost. It would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000.
The Associated Press contributed to this report.
